ArticleFrontiers in pharmacology2026
Camrelizumab plus CAPOX versus CAPOX for HER2-negative gastric or gastro-oesophageal junction adenocarcinoma: a cost-effectiveness analysis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03813784 (A Randomized, Open-label, Multi-center Phase III Clinical Study To Evaluate Camrelizumab), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Open-label, Multi-center Phase III Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study was to assess the cost-effectiveness of camrelizumab in combination with capecitabine plus oxaliplatin (CAPOX) compared to CAPOX for human epidermal growth factor receptor 2 (HER2)-negative advanced gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC) in China. Methods: A partitioned survival model was constructed to simulate the 10-year disease progression with HER2-negative advanced GC/GEJC treatment scenarios. Survival data for the model were sourced from NCT03813784 clinical trial. The costs considered in the model included drug costs, management costs for severe adverse events, subsequent treatment costs, and best supportive care costs. Health outcomes were measured in quality-adjusted life year (QALY). The willingness-to-pay (WTP) threshold was defined as 41,876.05 USD per QALY. Sensitivity analyses were conducted to assess the robustness of the model results. Results: In the overall study population, the camrelizumab plus CAPOX had an incremental cost of 10,688.44 USD and an additional 1.13 QALYs compared to the CAPOX group. This resulted in an incremental cost-effectiveness ratio (ICER) of 9,458.80 USD per QALY. In the PD-L1 positive subgroup, the addition of camrelizumab to CAPOX in this subgroup led to an incremental QALY gain of 1.17, resulting in an ICER of 9,183.07 USD per QALY. The ICER values observed in both groups were found to be below the WTP thresholds. The results of the one-way sensitivity analysis showed that changes in the input parameters did not substantially alter the conclusion. The probabilistic sensitivity analysis indicated that the probability of camrelizumab plus CAPOX being cost-effective was 100% at the WTP threshold of 41,876.05 USD per QALY. Conclusion: Camrelizumab with CAPOX demonstrates cost-effectiveness as a first-line treatment option for patients with advanced HER2-negative GC/GEJC. This regimen offers promising clinical outcomes while also being economically feasible within the context of China's healthcare system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.